Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: Long-term analysis of the previously published trial

Onkologie

Volumn 32, Issue 8-9, 2009, Pages 468-472

  Jassem, Jacek ^a   Pienkowski, Tadeusz ^b   Pluzanska, Anna ^c   Jelic, Svetislav ^d   Gorbunova, Vera ^e   Berzins, Juris ^f   Nagykalnai, Thomas ^g   Biganzoli, Laura ^h   Aloe, Alessandra ⁱ   Astier, Ludovic ⁱ   Munier, Stephane ⁱ  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^e Oncological Research Center   (Russian Federation)

^f RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^g UZSOKI HOSPITAL   (Hungary)

^h Hospital of Prato   (Italy)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

Breast cancer; Doxorubicin; Paclitaxel; Phase III study

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RISK ASSESSMENT; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EUROPE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PACLITAXEL; PREVALENCE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70249129810     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226210     Document Type: Article

References (9)

1. Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, Mayer F, Culine S, Dohoulou N, Bendahmane B: Phase II multieentre randomised study of doeetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyelophosphamide in metastatie breast cancer. Br J Cancer 2004;91:1466-1471.
2. Biganzoli L, Cufer T, Bruning P, Coleman R, Du-chateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatie breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002;20: 3114-3121.
3. Luck H, Thomssen C, Untch M, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Moebus V, Steinfeld D, Bauknecht T, Schroeder W, Jackisch C: Multicentric phase III study in first line treatment of advanced breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc ASCO 2000;19:73a (abstr).
4. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C, for the Central and Eastern Europe and Israel Paclitaxel Breast Cancer Study Group: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first line therapy for women with metastatie breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707-1715.
5. Mackey JR, Paterson A, Dirix LY, Dewar J, Chap L, Martin M, Chan S, Tang S-C, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Efremedis A, Appia F, Brunei E, Hatteville L, Azli N, Nabholtz J-M: Final results of the phase III randomized trial comparing doeetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatie breast cancer (MBC). Proc ASCO2002;21:35a (abstr).
6. Nabholtz J-M, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P for the TAX 306 Study Group: Doeetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatie breast cancer: results of a randomized multicenter phase III trial. J Clin Oncol 2003;21:968-975.
7. Bontenbal M, Creemers G-J, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C: Phase II to III study comparing doxorubicin and doeetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatie breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005;23:7081-7088.
8. Carmichael J: UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and taxol® (ET) in the first line treatment of women with metastatie breast cancer (MBC). Proc Am Soc Clin Oncol 2001;20:22a (abstr).
9. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 1982;38: 29-41.